The goal of seamless enterprise-wide image access and distribution faces a major obstacle: Health Level 7 message incompatibility continues to constitute a technical barrier to broader PACS adoption in cardiology and orthopedics.
The goal of seamless enterprise-wide image access and distribution faces a major obstacle: Health Level 7 message incompatibility continues to constitute a technical barrier to broader PACS adoption in cardiology and orthopedics.
Conformance to standard HL7 message format is the ultimate bridge over this obstacle, but sources predict it will take years before vendors fully adopt a standard message format that achieves total cross-platform compatibility. As a result, many institutions use brokers to interface information systems and PACS.
"Current trends are moving to a brokerless environment, with PACS embedded with HL7 interfaces and informatics-PACS alliances developing elegant integrations. But this could take 10 years or more to achieve," said Chris Walker, CEO of the California-based Cardio-Vascular Sales.
What progress has been made has occurred at a slower pace than most clinicians would prefer.
Excluding digital cardiac cath labs, PACS has penetrated only about 10% of hospital cardiology departments, according to Walker. Radiology PACS, on the other hand, is present in over 50% of U.S. hospitals.
Jacques Cornet, a vice president at Cedara Software, cited several other challenges to broader cardiology PACS adoption:
Many technology vendors who currently offer clinical PACS in this area provide solutions that limit institutional connectivity as either cardiology PACS or radiology PACS - not as a seamless, integrated enterprise-wide system.
"This approach only serves to develop further information/image silos within the healthcare enterprise," Cornet said.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.